Ellis Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Ellis Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13	Closed	-$8K	–	617
2022 Q3	$8K	Hold	13	–	–	﹤0.01%	606
2022 Q2	$7K	Hold	13	–	–	﹤0.01%	640
2022 Q1	$9K	Hold	13	–	–	﹤0.01%	639
2021 Q4	$8K	Hold	13	–	–	﹤0.01%	647
2021 Q3	$7K	Hold	13	–	–	﹤0.01%	651
2021 Q2	$7K	Buy	+13	New	+$6.59K	﹤0.01%	656

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ellis Investment Partners's REGN Position: Q4 2022 in Review

Ellis Investment Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 13 shares — an estimated $8K sold.

Ellis Investment Partners first reported a position in REGN in Q2 2021 and held it in 6 quarters. The position peaked at $9K in Q1 2022. 1,158 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Ellis Investment Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Ellis Investment Partners sold 13 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $8K.
Ellis Investment Partners first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 6 quarters.
Ellis Investment Partners's Regeneron Pharmaceuticals position peaked at $9K in Q1 2022.
1,158 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.